Shanghai Xinfeng Pharmaceutical Co., Ltd.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the oral administration of the test preparation sildenafil citrate orally dissolvable film (manufacturer: Shanghai Xinfeng Pharmaceutical Co., Ltd.) and The pharmacokinetic behavior of the reference preparation sildenafil citrate after oral dissolution in film (licensee: Viagra® Co., Ltd., trade name: Viagra®) was evaluated in vivo to evaluate the biological properties of the two preparations. Equivalence. Secondary purpose: To observe the safety of the test preparation sildenafil citrate orally dissolving film and the reference preparation sildenafil citrate orally dissolving film in healthy subjects; to evaluate the test preparation sildenafil citrate orally dissolving film Palatability (overall taste, off-flavor, sweetness, aroma, bitterness evaluation), gritty feeling, dissolution time, mucoadhesion and irritation of the orally dissolvable film of denafil and the reference preparation sildenafil citrate orally dissolvable film sex.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the oral administration of the test preparation bripiprazole orally dissolving film (manufacturer: Shanghai Xinfeng Pharmaceutical Co., Ltd.) and the reference preparation in the fasting/postprandial state. Evaluation of the pharmacokinetic behavior of bripiprazole orally disintegrating tablets (licensee: Otsuka Pharmaceutical Co., Ltd., trade name: Rexulti® OD) in healthy subjects Bioequivalence of the two formulations. Secondary purpose: To observe the safety of the test preparation bripiprazole orally dissolving films and the reference preparation bripipiprazole orally disintegrating tablets in healthy subjects; to evaluate the test preparation bripiprazole orally dissolving films and the reference preparation bripipiprazole orally dissolving tablets The palatability (overall taste, off-flavor, sweetness, aroma, bitterness evaluation), gritty feel, disintegration/dissolution time, mucoadhesion and irritation of the preparation Bripipiprazole orally disintegrating tablets (without water supply).

Primary objective: A single-center, randomized, open, two-period crossover, single oral trial design was used to compare the differences in the degree and rate of absorption of ondansetron orodispersible film (specification: 8 mg) provided by Shanghai Xinfeng Pharmaceutical Co., Ltd. and ondansetron orodispersible film (specification: 8 mg) licensed by Norgine Pharmaceuticals Limited in healthy Chinese people under fasting and fed conditions. Secondary objective: Evaluate the safety and tolerability of ondansetron orodispersible film (specification: 8 mg) provided by Shanghai Xinfeng Pharmaceutical Co., Ltd. and ondansetron orodispersible film (specification: 8 mg) licensed by Norgine Pharmaceuticals Limited under fasting and fed conditions.